Abstract 584P
Background
CNS metastases are associated with high clinical burden and mortality risk in patients with advanced EGFR+ NSCLC. The phase III AENEAS study showed that aumolertinib, a novel third-generation EGFR-TKI, significantly improved median CNS PFS in comparison to gefitinib in treatment-naive EGFR+ NSCLC patients with CNS metastases (29.0 vs 8.3months, hazard ratios: 0.319). In this study, we explore whether aumolertinib could potentially delay or prevent symptomatic CNS metastases in EGFR+ NSCLC patients without baseline CNS metastasis.
Methods
We included all consecutive EGFR+ NSCLC patients who underwent first or second-line aumolertinib treatment without baseline CNS metastasis (April 2021 to February 2023). We estimated the cumulative incidence of subsequent symptomatic CNS metastases, CNS median PFS, and their associated risk factors using the Kaplan–Meier method and the log-rank test. Images obtained upon EGFR-TKI initiation and at the time of EGFR-TKI treatment failure. Follow-up brain scans were not mandatory, typically after the appearance of indicative symptoms. Supplementary follow-up telephone interviews were also employed.
Results
A total of 88 pts were enrolled. At data cutoff,the median follow-up was 21 months,with only 1 pt experienced symptomatic CNS metastases. The cumulative incidence of symptomatic CNS metastasis at 12, 18, and 24 months were 0%, 1.538%, and 1.538%, respectively.For the 62 pts who received second-line aumolertinib,the cumulative incidence of symptomatic CNS metastases at the same time points was 0%. However, the cumulative incidence curves of symptomatic CNS metastasis tended to reach a plateau after approximately 18 months.The cumulative incidence with aumolertinib was lower than historical data from first-generation EGFR-TKIs and also demonstrated a declining trend compared to historical data from the retrospective study of Osimertinib (1-2% at 12 months; 2-3% at 24 months; 11.8% at 36 months).
Conclusions
This is the first study to demonstrate that Aumolertinib can reduce the risk of symptomatic CNS metastasis in EGFR+ NSCLC patients without baseline CNS metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract